Poxel SA

Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline

Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team

Latest News

Sep 13, 2018

Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K

Poxel has also established a Japanese subsidiary in Tokyo Both events are strategic commitments to the Japanese and Asian markets Lyon, France, September 13, 2018 – POXEL SA (Euronext – POXEL -…

Read this Press Release

Sep 4, 2018

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes…

Read this Press Release

Aug 30, 2018

Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs

Poxel acquires exclusive, worldwide ownership to DRX-065 (deuterium-stabilized R-pioglitazone), a clinical stage program being pursued for the treatment of NASH …

Read this Press Release